[ad_1]
The immune response to COVID-19 vaccines in patients with certain immunosuppressed conditions will be examined in a new study.
Patients with cancer, inflammatory arthritis, kidney or liver disease, or those who undergo a stem cell transplant may be more likely to have more serious complications from the coronavirus.
Such underlying medical conditions and the treatment some patients receive as part of their care can weaken the immune system, so they have been prioritized for treatment. COVID-19 vaccine.
However, the researchers state that current evidence suggests that people with these medical conditions may not get optimal protection from established vaccines.
Therefore, the new Octave trial seeks to determine the effectiveness of coronavirus vaccines in these groups of patients clinically at risk.
Funded by the Medical Research Council (MRC), the trial is a collaborative research project involving groups from the Universities of Glasgow, Birmingham, Oxford, Liverpool, Imperial College London, and Leeds Teaching Hospitals NHS Trust.
Study leader Professor Iain McInnes, University of Glasgow, said: “We urgently need to understand whether patient populations with chronic diseases such as cancer, inflammatory arthritis, and kidney and liver disease are likely to be well protected by the current COVID. “. 19 vaccines.
“The Octave study will provide us with invaluable new information to help us answer such questions from our patients and their families.”
The study will look at the effectiveness of COVID-19 jabs to be used in the UK in 2021, in up to 5,000 people within these patient populations.
The investigation will analyze the effectiveness of COVID-19 hits
Researchers will determine the COVID-19 immune response of patients using a variety of state-of-the-art immunological tests performed on blood samples taken before and / or after receiving the vaccine.
They have started recruiting patients at sites across the UK and will compare the results of the study group with control groups of healthy people, without these underlying diseases, who also received coronavirus injections.
It is not yet known how long COVID-19 vaccines provide immunity, and there may be a continued need for vaccination against the disease in the years to come.
Professor Fiona Watt, CEO of the Medical Research Council, which funded the study, said: “This study is investigating the response to new COVID-19 vaccines in people whose immune systems make them more vulnerable to Covid-19 and other infections.
“This will help ensure that those most at risk of infection receive the best possible protection.”
